Literature DB >> 3922531

Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor.

I M Nilsson, H Ljungnér, L Tengborn.   

Abstract

Fibrinolytic components after venous occlusion and concentrations of tissue plasminogen activator inhibitor were studied in 100 consecutive patients with confirmed recurrent deep vein thrombosis or pulmonary embolism. After 20 minutes of venous occlusion the fibrinolytic response was decreased in 33 patients, as measured both amidolytically with S-2251 and on fibrin plates. Two different mechanisms responsible for the poor fibrinolytic response could be distinguished. Twenty two of the patients in whom the response was poor released normal amounts of tissue plasminogen activator antigen, as assayed by immunoradiometric assay, but had appreciably increased concentrations of tissue plasminogen activator inhibitor. The 11 other patients in whom the response was poor had both low tissue plasminogen activator activities and low tissue plasminogen activator antigen concentrations but normal concentrations of tissue plasminogen activator inhibitor. The results show not only that defective synthesis or release of tissue plasminogen activator may be important in the pathogenesis of venous thrombosis but also that a large group of patients with thrombosis have an increased concentration of the inhibitor to tissue plasminogen activator.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3922531      PMCID: PMC1415704          DOI: 10.1136/bmj.290.6480.1453

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  30 in total

1.  Severe thrombotic disease in a young man with bone marrow and skeletal changes and with a high content of an inhibitor in the fibrinolytic system.

Authors:  I M NILSSON; H KROOK; N H STERNBY; E SODERBERG; N SODERSTROM
Journal:  Acta Med Scand       Date:  1961-03

2.  Synthesis of a fibrinolytic activator and inhibitor by endothelial cells.

Authors:  D J Loskutoff; T E Edgington
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

Review 3.  Coagulation, fibrinolysis and venous thrombosis.

Authors:  I M Nilsson
Journal:  Triangle       Date:  1977

4.  Two genetic variants of von Willebrand's disease.

Authors:  L Holmberg; I M Nilsson
Journal:  N Engl J Med       Date:  1973-03-22       Impact factor: 91.245

5.  Impairment of the diurnal fibrinolytic response in man. Effects of aging, type IV hyperlipoproteinemia, and coronary artery disease.

Authors:  D R Rosing; D R Redwood; P Brakman; T Astrup; S E Epstein
Journal:  Circ Res       Date:  1973-06       Impact factor: 17.367

6.  "Fibrinolytic capacity" in healthy volunteers as estimated from effect of venous occlusion of arms.

Authors:  B R Robertson; M Pandolfi; I M Nilsson
Journal:  Acta Chir Scand       Date:  1972

7.  Defective fibrinolysis in blood and vein walls in recurrent "idiopathic" venous thrombosis.

Authors:  S Isacson; I M Nilsson
Journal:  Acta Chir Scand       Date:  1972

8.  Heparin cofactor activity measured with an amidolytic method.

Authors:  O R Odegard; M Lie; U Abildgaard
Journal:  Thromb Res       Date:  1975-04       Impact factor: 3.944

9.  A family with thromboembolic disease associated with deficient fibrinolytic activity in vessel wall.

Authors:  L Johansson; U Hedner; I M Nilsson
Journal:  Acta Med Scand       Date:  1978

10.  Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate.

Authors:  A C Teger-Nilsson; P Friberger; E Gyzander
Journal:  Scand J Clin Lab Invest       Date:  1977-09       Impact factor: 1.713

View more
  29 in total

1.  Extending the capabilities of targeted molecular dynamics: simulation of a large conformational transition in plasminogen activator inhibitor 1.

Authors:  P Krüger; S Verheyden; P J Declerck; Y Engelborghs
Journal:  Protein Sci       Date:  2001-04       Impact factor: 6.725

Review 2.  Acquired and congenital clotting syndromes.

Authors:  F W Blaisdell
Journal:  World J Surg       Date:  1990 Sep-Oct       Impact factor: 3.352

Review 3.  Insulin resistance and polycystic ovary syndrome.

Authors:  David A Ehrmann
Journal:  Curr Diab Rep       Date:  2002-02       Impact factor: 4.810

4.  Fibrinolytic markers and vasodilatory capacity following acute exercise among men of differing training status.

Authors:  Tracy Baynard; Helena M Jacobs; Craig M Kessler; Jill A Kanaley; Bo Fernhall
Journal:  Eur J Appl Physiol       Date:  2007-08-04       Impact factor: 3.078

5.  Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1.

Authors:  M P Bevilacqua; R R Schleef; M A Gimbrone; D J Loskutoff
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

6.  Induction of plasminogen activator inhibitor 1 gene expression in murine liver by lipopolysaccharide. Cellular localization and role of endogenous tumor necrosis factor-alpha.

Authors:  C Fearns; D J Loskutoff
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

7.  Indications of vascular endothelial cell dysfunction in systemic lupus erythematosus.

Authors:  M A Byron; M J Allington; H M Chapel; A G Mowat; S A Cederholm-Williams
Journal:  Ann Rheum Dis       Date:  1987-10       Impact factor: 19.103

8.  Effect of garlic on platelet aggregation in patients with increased risk of juvenile ischaemic attack.

Authors:  H Kiesewetter; F Jung; E M Jung; C Mroweitz; J Koscielny; E Wenzel
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  Postoperative venous thromboembolism and brain tumors: Part II. Hemostatic profile.

Authors:  R Sawaya; P Glas-Greenwalt
Journal:  J Neurooncol       Date:  1992-10       Impact factor: 4.130

10.  Association of congenital cardiovascular malformations with 33 single nucleotide polymorphisms of selected cardiovascular disease-related genes.

Authors:  Karen Kuehl; Christopher Loffredo; Edward J Lammer; David M Iovannisci; Gary M Shaw
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2010-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.